Lorine Arias Bonifácio Teixeira

Lorine Arias Bonifácio Teixeira

Auto-generated profile, based on publicly available information

Lorine Arias Bonifácio Teixeira

Department of Radiotherapy, Faculty of Medicine University of São Paulo, São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2022 in RadioGraphics
Verified
Journal Article
Closed access
PRPedro H. P. Rocha
Pedro H. P. Rocha
RRRaphael M. Reali
Raphael M. Reali
MDMarcos Decnop
Marcos Decnop
SSSoraia A. Souza
Soraia A. Souza
LTLorine A. B. Teixeira
Lorine A. B. Teixeira
MGMarcio Garcia
Marcio Garcia
Radiation therapy has an essential role in the treatment of head and neck malignancies, but radiation-induced adverse effects remain a clinical issue and are recognizable at CT and MRI. Whether used as a single modality or as part of a combined approach, radiation therapy (RT) plays an essential role in the treatment of several head and neck malignancies. Despite the improvement i...

16 April 2026 in BMC Cancer
Verified
Journal Article
Open access
PDF file
DNDiego Wallace Nascimento
Diego Wallace Nascimento
JFJosé Roberto Filassi
José Roberto Filassi
ÂCÂngela Francisca Trinconi Cunha
Ângela Francisca Trinconi Cunha
RGRodrigo Gonçalves
Rodrigo Gonçalves
MKMarina Bellati Kuller
Marina Bellati Kuller
BMBruna Salani Mota
Bruna Salani Mota
Background: The COVID-19 pandemic disrupted healthcare systems worldwide and substantially affected breast cancer care. International reports have described delays in diagnosis, stage, and modifications in treatment strategies, however, little is known about how the pandemic has affected the entire sequence of steps from diagnosis to treatment initiation and completion within the Brazilian public healthcare system. Methods: This retrospective cohort study followed the STROBE guidelines and was conducted at a high-volume public cancer center in São Paulo, Brazil. A total of 1,306 women diagnosed with invasive or in situ breast cancer were included: 755 patients in the prepandemic period (March 2018–February 2019) and 551 patients in the pandemic period (March 2020–February 2021). Clinical, pathological, treatment, and time-related variables along the care pathway were extracted from electronic medical records and compared using appropriate statistical tests, with significance set at p < 0.05. Results: A 32% reduction in the number of treated patients occurred during the pandemic (551 vs. 755). Patients who were diagnosed during the pandemic were younger (48.3 vs. 53.6 years; p < 0.001) and presented with more advanced clinical stages, including higher rates of cT3–T4 tumors and nodal involvement ( p < 0.001). The use of neoadjuvant therapy increased from 36.8% to 49%, particularly among early-stage and luminal B tumors. Key intervals across the care pathway were significantly prolonged, including time to initial treatment and completion of adjuvant therapy. Radiotherapy practices have shifted toward hypofractionated protocols. Conclusion: The first year of the COVID-19 pandemic was associated with fewer treated patients, stage migration toward more advanced disease, greater reliance on neoadjuvant therapy, and prolonged time intervals along the care pathway from diagnosis to treatment initiation and completion. These findings highlight the need for resilient oncology systems, protected treatment pathways, and strengthened care coordination to mitigate the impact of future healthcare crises.